SCHEMBL2746500

SCHEMBL2746500

C[C](C(N)=O)C(=O)N1CCC(C(=O)NN)CC1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 1/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 2/20 0.36
PTPN2 P17706 1/20 0.34
PTPN1 P18031 1/20 0.34
PTPN6 P29350 1/20 0.34
POLB P06746 1/20 0.34
HSD17B10 Q99714 1/20 0.33
MAPK1 P28482 1/20 0.33
TSHR P16473 1/20 0.33
REV1 Q9UBZ9 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2745870 0.82 GAA (0.51) GAASMN1; SMN2POLBTSHR
SCHEMBL3886733 0.80 HDAC3 (0.45) SMN1; SMN2KMT2AMEN1HSD17B10MAPK1
SCHEMBL2744881 0.80 LMNA (0.47) GAAMAPTLMNAHSD17B10TSHR
SCHEMBL2745755 0.77 HTT (0.36) GAAMAPT
SCHEMBL5542679 0.76 LMNA (0.41) GAASMN1; SMN2KMT2AMEN1LMNA
SCHEMBL2746604 0.75 HPGD (0.56) SMN1; SMN2KMT2AMEN1LMNATSHR
SCHEMBL2746501 0.75 LMNA (0.40) GAASMN1; SMN2KMT2AMEN1LMNA
SCHEMBL1501616 0.74 SMN1; SMN2 (0.40) GAASMN1; SMN2KMT2AMEN1LMNA
SCHEMBL315026 0.73 HPGD (0.60) SMN1; SMN2KMT2APTPN2PTPN1PTPN6
SCHEMBL2746390 0.73 RECQL (0.57) SMN1; SMN2KMT2AMEN1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367666-B2 3-carbamoyl-2-pyridone derivatives SHIONOGI & CO., LTD. (JP) 2013-02-05 US disclosed
US-20120208813-A1 3-CARBAMOYL-2-PYRIDONE DERIVATIVES SHIONOGI & CO., LTD. 2012-08-16 US disclosed
US-8178681-B2 methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency SHIONOGI & CO., LTD. (JP) 2012-05-15 US disclosed
US-20080103139-A1 3-Carbamoyl-2-Pyridone Derivative SHIONOGI & CO. LTD. (JP) 2008-05-01 US disclosed
EP-1806342-A1 3-CARBAMOYL-2-PYRIDONE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2007-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208813-A1 3-CARBAMOYL-2-PYRIDONE DERIVATIVES CNR2, CNR1, HRH4 GAA 4010/4885SMN1; SMN2 4550/4885KMT2A 2255/4885
US-20080103139-A1 3-Carbamoyl-2-Pyridone Derivative CNR1, CNR2, HRH4 GAA 4580/4885SMN1; SMN2 4482/4885KMT2A 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.